Safety and efficacy of ritonavir-boosted atazavavir (ATV/r) compared with ritonavir-boosted darunavir (DRV/r) or raltegravir in HIV-1 infected patients: The Italian Cohort Naives Antinetrovirals (ICONA) foundation study

Trial Profile

Safety and efficacy of ritonavir-boosted atazavavir (ATV/r) compared with ritonavir-boosted darunavir (DRV/r) or raltegravir in HIV-1 infected patients: The Italian Cohort Naives Antinetrovirals (ICONA) foundation study

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Atazanavir/ritonavir (Primary) ; Darunavir/ritonavir (Primary) ; Raltegravir (Primary) ; Abacavir; Emtricitabine; Lamivudine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Mar 2018 New trial record
    • 01 Mar 2018 Results published in the HIV Clinical Trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top